Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Depreciation & Amortization (CF) (2016 - 2025)

Bio-Techne (TECH) has 17 years of Depreciation & Amortization (CF) data on record, last reported at $24.7 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 8.77% year-over-year to $24.7 million; the TTM value through Dec 2025 reached $103.7 million, down 6.2%, while the annual FY2025 figure was $109.9 million, 1.62% down from the prior year.
  • Depreciation & Amortization (CF) reached $24.7 million in Q4 2025 per TECH's latest filing, up from $24.3 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $28.5 million in Q3 2023 and bottomed at $21.1 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $26.2 million, with a median of $26.8 million recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): grew 20.21% in 2022, then fell 13.49% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $25.1 million in 2021, then rose by 6.38% to $26.7 million in 2022, then increased by 4.12% to $27.8 million in 2023, then decreased by 2.59% to $27.1 million in 2024, then decreased by 8.77% to $24.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $24.7 million in Q4 2025, $24.3 million in Q3 2025, and $27.1 million in Q2 2025.